Welcome to our dedicated page for Syneos Health news (Ticker: SYNH), a resource for investors and traders seeking the latest updates and insights on Syneos Health stock.
Syneos Health (SYNH) is a leading provider of integrated clinical and commercial solutions for the biopharmaceutical industry. This page aggregates official press releases, regulatory filings, and material updates related to SYNH's operations and market position.
Investors and industry professionals will find timely updates on clinical trial milestones, strategic partnerships, and financial performance. Our curated collection ensures access to primary source information critical for informed decision-making in the evolving healthcare sector.
The repository includes updates on regulatory developments, service expansions, and leadership changes, maintained with strict adherence to factual reporting. Content is organized chronologically for efficient tracking of corporate developments.
Bookmark this page for streamlined access to SYNH's latest announcements. Combine regular monitoring with professional financial advice when evaluating investment opportunities in the dynamic biopharma services market.
Phil Inc. has announced an exclusive partnership with Syneos Health (NASDAQ:SYNH), aiming to enhance patient prescription access through a comprehensive commercialization solution. Phil will provide HUB-related services exclusively for Syneos, which will in turn offer Phil preferred outsourced services. This collaboration focuses on streamlining the prescription process, ensuring patients can quickly and affordably start and maintain their therapies. Both companies emphasize their commitment to improving patient outcomes and the overall prescription management experience.
Syneos Health (Nasdaq:SYNH) will announce its Q3 2022 financial results on November 4, 2022, before an earnings call at 8:00 a.m. ET. Participants can join the call by registering in advance through their website. A replay of the webcast will be accessible after 1:00 p.m. on the same day. Syneos Health, a fully integrated biopharmaceutical solutions organization, employs over 29,000 professionals across 110 countries, focusing on improving the delivery of therapies to patients through advanced integration of clinical, medical, and commercial capabilities.
Syneos Health (Nasdaq: SYNH) announced the appointment of William E. Klitgaard to its Board of Directors, marking his return after resigning in May 2022. Klitgaard brings extensive financial experience and familiarity with the company, enhancing Board strength. The company also expressed gratitude to Todd M. Abbrecht, who is stepping down. Klitgaard will serve as a Class II director and on the Audit Committee, maintaining a Board composition of 10 directors, 9 of whom are independent. This leadership change is expected to bolster oversight of Syneos Health's strategic direction.
Syneos Health (Nasdaq:SYNH) has announced an expanded partnership with Datavant to enhance clinical trial tokenization and analytics capabilities. This collaboration aims to accelerate the development and commercialization of new therapies by utilizing Datavant Switchboard and its data ecosystem. The integration will improve the efficiency of clinical trials, enhance Medical Affairs, Market Access, and Commercial Analytics, and optimize product launch trajectories. Datavant's Privacy Hub will facilitate compliant data sharing, reinforcing Syneos Health's position in the biopharmaceutical solutions sector.
Syneos Health (Nasdaq:SYNH) will be represented by CEO Michelle Keefe and CFO Jason Meggs at the 2022 Baird Global Healthcare Conference on September 13, 2022, at 2:00 p.m. ET. A webcast of their presentation, including materials and a replay, will be available on the Company’s Investor Relations website.
physIQ has announced a strategic collaboration with InCarda Therapeutics to advance InRhythm™, an inhaled treatment for atrial fibrillation (AF). This Phase III RESTORE-1 study employs innovative trial design using wearable sensors and FDA-cleared biomarkers to screen and enroll 400 patients efficiently across Europe and North America. The study aims to demonstrate faster restoration of normal sinus rhythm through real-time data acquisition. The collaboration is expected to enhance patient enrollment and treatment efficacy for the significant population affected by AF.
Syneos Health reported Q2 2022 revenue of $1,360.7 million, reflecting a 6.1% increase year-over-year, driven by Clinical and Commercial Solutions growth. Clinical Solutions revenue rose 3.3%, while Commercial Solutions increased 15.7%. However, net new business awards fell 34.2% year-over-year, with a book-to-bill ratio of 0.92x. GAAP net income surged 85.5% to $77.7 million, achieving $0.75 EPS. The company revised its FY 2022 guidance, anticipating lower reimbursable expenses and foreign exchange impacts.
Syneos Health (Nasdaq:SYNH) will release its Q2 2022 financial results on August 2, 2022, before its earnings call at 9:00 a.m. ET. Investors can access the call via the company's Investor Relations webpage. A replay will be available post-call. As a fully integrated biopharmaceutical solutions organization, Syneos Health focuses on enhancing customer success through a blend of clinical development, medical affairs, and commercial capabilities. The company operates in over 110 countries, leveraging advanced technologies and insights to expedite therapy delivery.
Syneos Health (Nasdaq:SYNH) announced its participation in two key investor conferences. CEO Michelle Keefe and CFO Jason Meggs will present at the 42nd Annual William Blair Growth Stock Conference in Chicago on June 6, 2022, at 3:20 p.m. CT and the Jefferies Healthcare Conference in New York on June 8, 2022, at 3:30 p.m. ET. Both events will feature live webcasts accessible through the Company’s Investor Relations website. Syneos Health is a fully integrated biopharmaceutical solutions organization dedicated to advancing customer success.
FAQ
What is the market cap of Syneos Health (SYNH)?
